Based in Leederville, Western Australia, Emyria (ASX: EMD) is a data-based healthcare company. They’re passionate about finding effective treatments for conditions with only side effect-ridden, insufficient or non-existent treatments. Emyria works in the medical cannabis industry and psychedelic drug industry. 

Emyria is also the owner of Emerald Clinics (ASX: EMD), an alternative healthcare provider that serves 5,000+ Australians and patients in the UK. 

You may know Emyria from its work with MDMA-analogues with the University of Western Australia, its efforts to develop a synthetic cannabinoid medication with AltraSciences or its clinical trial on Autism Spectrum Disorder and medical cannabis with Zelira. 

In 2021, Emyria was accepted into Palantir’s Foundry Builders Platform. The program gives participating companies access to some of the world’s most advanced data programs. 

Emyria’s name comes from the word “myriad”, which you can see in their slogan “Myriad data. Individual Care.”